부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.virol.2007.10.006 Byline: Maria Cubero (a)(b)(c), Juan Ignacio Esteban (a)(b)(c), Teresa Otero (a), Silvia Sauleda (c)(d), Marta Bes (c)(d), Rafael Esteban (a)(b)(c), Jaume Guardia (a)(b)(c), Josep Quer (a)(b)(c) Keywords: HCV-NS3; Inhibitor; Mutant; Resistant; Untreated; Patient Abstract: An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with anti-NS3-protease inhibitors. Author Affiliation: (a) Liver Unit, Department of Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain (b) Universitat AutA[sup.2]noma de Barcelona. UAB Bellaterra, Spain (c) CIBER de Enfermedades Hepaticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain (d) Banc de Sang i de Teixits, Institut Catala de la Salut, Barcelona, Spain Article History: Received 7 September 2007; Revised 17 September 2007; Accepted 5 October 2007